Literature DB >> 10883664

Aberrant expression of cyclin A in head and neck cancer.

M Lotayef1, G D Wilson, F M Daley, H K Awwad, T Shouman.   

Abstract

Cyclin A expression was studied in a series of 65 squamous cell carcinomas of the head and neck (HNSCC) and compared with known markers of proliferation, iododeoxyuridine (IdUrd) and Ki-67, to assess whether aberrant expression was prevalent. Patients had previously been administered IdUrd to study cell kinetics in relation to outcome of radiotherapy. The data showed that all three parameters were highly correlated although the absolute values were different. The median labelling indices (LI) for IdUrd, cyclin A and Ki-67 were 10.7, 17.1 and 30.8% respectively, reflecting the known pattern of differential cell cycle expression. However, there were a significant number of cases in which an unexpected relationship between cyclin A and either IdUrd or Ki-67 was present. Some of these were attributable to overexpression but others indicated underexpression. Although the greater variability and range of cyclin A expression, coupled with its more closely associated role in cell cycle regulation, might suggest that it may be a more informative marker for cell proliferation than Ki-67, the aberrant expression seen in over one third of cases would indicate that caution should be exercised in interpreting cyclin A as a surrogate marker of proliferation in HNSCC.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10883664      PMCID: PMC2374545          DOI: 10.1054/bjoc.2000.1193

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  15 in total

Review 1.  Tpot and head and neck cancer: where are we now?

Authors:  G D Wilson
Journal:  Anticancer Res       Date:  1998 Nov-Dec       Impact factor: 2.480

Review 2.  Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer.

Authors:  M Hall; G Peters
Journal:  Adv Cancer Res       Date:  1996       Impact factor: 6.242

Review 3.  Bromodeoxyuridine: a diagnostic tool in biology and medicine, Part II: Oncology, chemotherapy and carcinogenesis.

Authors:  F Dolbeare
Journal:  Histochem J       Date:  1995-12

4.  The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma: a comparison with cyclins A and B1, Ki-67, proliferating cell nuclear antigen, and p34cdc2.

Authors:  B V Kallakury; C E Sheehan; S J Rhee; H A Fisher; R P Kaufman; M D Rifkin; J S Ross
Journal:  Cancer       Date:  1999-04-01       Impact factor: 6.860

5.  Expression of cyclin A and D proteins in prostate cancer and their relation to clinopathological variables and patient survival.

Authors:  S Aaltomaa; M Eskelinen; P Lipponen
Journal:  Prostate       Date:  1999-02-15       Impact factor: 4.104

Review 6.  Cancer cell cycles.

Authors:  C J Sherr
Journal:  Science       Date:  1996-12-06       Impact factor: 47.728

7.  Immunocytochemical detection of cyclin A and cyclin D in formalin-fixed, paraffin-embedded tissues: novel, pertinent markers of cell proliferation.

Authors:  B Bodey; R T Williams; D A Carbonaro-Hall; A Horvath; V T Tolo; J V Luck; C R Taylor; F L Hall
Journal:  Mod Pathol       Date:  1994-10       Impact factor: 7.842

8.  Determination of the prognostic significance of unscheduled cyclin A overexpression in patients with esophageal squamous cell carcinoma.

Authors:  M Furihata; T Ishikawa; A Inoue; C Yoshikawa; H Sonobe; Y Ohtsuki; K Araki; S Ogoshi
Journal:  Clin Cancer Res       Date:  1996-10       Impact factor: 12.531

9.  Cyclin A overexpression in carcinoma of the renal pelvis and ureter including dysplasia: immunohistochemical findings in relation to prognosis.

Authors:  M Furihata; Y Ohtsuki; H Sonobe; T Shuin; A Yamamoto; N Terao; M Kuwahara
Journal:  Clin Cancer Res       Date:  1997-08       Impact factor: 12.531

10.  Cyclins as markers of tumor proliferation: immunocytochemical studies in breast cancer.

Authors:  A Dutta; R Chandra; L M Leiter; S Lester
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.